Ken Griffin Theravance Biopharma, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$7.66 - $10.25 $14,554 - $19,475	-1,900 Reduced 61.29%	1,200 $9,000
Q2 2024 Aug 14, 2024	BUY	$8.29 - $9.92 $6,631 - $7,936	800 Added 34.78%	3,100 $26,000
Q1 2024 May 15, 2024	BUY	$8.22 - $11.59 $18,084 - $25,498	2,200 Added 2200.0%	2,300 $20,000
Q4 2023 Feb 14, 2024	BUY	$8.58 - $11.4 $858 - $1,140	100 New	100 $1,000
Q2 2023 Aug 14, 2023	SELL	$10.16 - $11.92 $248,920 - $292,040	-24,500 Reduced 83.05%	5,000 $51,000
Q1 2023 May 15, 2023	SELL	$9.87 - $11.44 $36,519 - $42,328	-3,700 Reduced 11.14%	29,500 $320,000
Q4 2022 Feb 14, 2023	BUY	$9.65 - $11.34 $320,380 - $376,488	33,200 New	33,200 $372,000

122

47.3M

200

12.8K

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $640M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.